TOSEDOSTAT PLUS LOW DOSE CYTARABINE COMBO INDUCES A HIGH RATE OF RESPONSES THAT CAN BE PREDICTED BY GENETIC PROFILING IN AML: FINAL RESULTS OF A PHASE II MULTICENTER STUDY

被引：0

作者：

Visani, G. ^{[1
]}

Loscocco, F. ^{[1
]}

Fuligni, F. ^{[2
]}

Zuffa, E. ^{[3
]}

Sensi, A. ^{[4
]}

Zaccaria, A. ^{[3
]}

Musuraca, G. ^{[5
]}

Giannini, B. ^{[4
]}

Lucchesi, A. ^{[5
]}

Fabbri, F. ^{[5
]}

Mianulli, A. M. ^{[6
]}

Tosi, P. ^{[6
]}

Tonelli, M. ^{[4
]}

Candoni, A. ^{[7
]}

Fanin, R. ^{[7
]}

Sparaventi, G. ^{[1
]}

Gobbi, M. ^{[8
]}

Clavio, M. ^{[8
]}

Rocchi, M. ^{[9
]}

Piccaluga, P. ^{[2
]}

Isidori, A. ^{[1
]}

机构：

[1] Hematol & Stem Cell Transplant Ctr, AORMN, Pesaro, Italy

[2] Univ Bologna, S Orsola M Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Hematopatol Sect, Bologna, Italy

[3] Ravenna Hosp, Hematol, Ravenna, Italy

[4] Ctr Serv Lab Unico AVR, Genet Med, Pievesestina Di Cesana, Italy

[5] IRST Meldola, Oncohematol, Meldola, Italy

[6] Rimini Hosp, Hematol, Rimini, Italy

[7] Azienda Osped Univ S Maria Misericordia, Ctr Trapianti & Terapie Cellulari Carlo Melzi DIS, Clin Ematol, Udine, Italy

[8] Univ Genoa, Hematol, Genoa, Italy

[9] Univ Urbino, Inst Biomath, I-61029 Urbino, Italy

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P564

引用

页码：215 / 215

页数：1

共 44 条

[1] TOSEDOSTAT PLUS LOW DOSE CYTARABINE COMBO INDUCES A HIGH RATE OF RESPONSES THAT CAN BE PREDICTED BY GENETIC PROFILING IN AML: FINAL RESULTS OF A PHASE II MULTICENTER STUDY
Isidori, A.
Loscocco, F.
Fuligni, F.
Zuffa, E.
Sensi, A.
Zaccaria, A.
Musuraca, G.
Giannini, B.
Lucchesi, A.
Fabbri, F.
Mianulli, A. M.
Tosi, P.
Tonelli, M.
Candoni, A.
Fanin, R.
Sparaventi, G.
Gobbi, M.
Clavio, M.
Rocchi, M.
Piccaluga, P. P.
Visani, G.
HAEMATOLOGICA, 2015, 100 : 10 - 10
[2] Tosedostat Plus Low Dose Cytarabine Induces a High Rate of Responses That Can be Predicted By Genetic Profiling in Elderly AML
Visani, Giuseppe
Loscocco, Federica
Fuligni, Fabio
Zuffa, Eliana
Sensi, Alberto
Zaccaria, Alfonso
Musuraca, Gerardo
Giannini, Barbara
Lucchesi, Alessandro
Fabbri, Francesca
Mianulli, Anna Maria
Tosi, Patrizia
Tonelli, Michela
Candoni, Anna
Fanin, Renato
Sparaventi, Giovanni
Gobbi, Marco
Clavio, Marino
Rocchi, Marco
Piccaluga, Pier Paolo
Isidori, Alessandro
BLOOD, 2015, 126 (23)
[3] LOW-DOSE LENALIDOMIDE AND CYTARABINE COMBO PRODUCES A HIGH COMPLETE REMISSION RATE THAT CAN BE PREDICTED BY GENETIC PROFILING IN AML PATIENTS AGED ≥70 YEARS: FINAL RESULTS OF A PHASE II STUDY
Isidori, A.
Ferrara, F.
Di Raimondo, F.
Loscocco, F.
Fuligni, F.
Gazzola, A.
Rossi, M.
Laginestra, A.
Caraci, M. R.
Zammit, V.
Spina, E.
Sparaventi, G.
Malerba, L.
Rocchi, M.
Gabucci, E.
Clissa, C.
Piccaluga, P. P.
Visani, G.
HAEMATOLOGICA, 2015, 100 : 215 - 215
[4] LOW-DOSE LENALIDOMIDE AND CYTARABINE COMBO PRODUCES AN HIGH COMPLETE REMISSION RATE THAT CAN BE PREDICTED BY GENETIC PROFILING IN AML PATIENTS AGED ≥70 YEARS: FINAL RESULTS OF A PHASE II STUDY
Visani, G.
Ferrara, F.
Di Raimondo, F.
Loscocco, F.
Fuligni, F.
Gazzola, A.
Rossi, M.
Laginestra, A.
Caraci, M. R.
Spina, E.
Zammit, V.
Sparaventi, G.
Malerba, L.
Rocchi, M.
Gabucci, E.
Clissa, C.
Piccaluga, P. P.
Isidori, A.
HAEMATOLOGICA, 2015, 100 : 9 - 10
[5] Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML
Zeidner, Joshua F.
Vincent, Benjamin G.
Esparza, Sonia
Ivanova, Anastasia
Moore, Dominic T.
Foster, Matthew C.
Coombs, Catherine C.
Jamieson, Katarzyna
Van Deventer, Hendrik W.
Blanchard, Laura
Churchwell, William
Frank, Cassiopeia
Gallagher, Sean
Matson, Melissa
Reed, Ashley
Vogler, Nancy
Webster, Jonathan
Prince, Gabrielle T.
DeZern, Amy E.
Smith, B. Douglas
Levis, Mark J.
Luznik, Leo
Serody, Jonathan S.
Gojo, Ivana
BLOOD, 2019, 134
[6] LOW-DOSE LENALIDOMIDE PLUS LOW DOSE CYTARABINE INDUCE COMPLETE REMISSION THAT CAN BE PREDICTED BY GENETIC PROFILING IN VERY ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS
Isidori, A.
Ferrara, F.
Di Raimondo, F.
Loscocco, F.
Piccaluga, P. Paolo
Fuligni, F.
Gazzola, A.
Rossi, M.
Laginestra, A.
Caraci, M.
Izzo, T.
Riccardi, C.
Barulli, S.
Guiducci, B.
Picardi, P.
Ricciardi, T.
Sparaventi, G.
Rocchi, M.
Visani, G.
HAEMATOLOGICA, 2013, 98 : 246 - 246
[7] Low-Dose Lenalidomide Plus Low Dose Cytarabine Induce Complete Remission That Can Be Predicted By Genetic Profiling In Very Elderly Acute Myeloid Leukemia Patients
Visani, Giuseppe
Di Raimondo, Francesco
Ferrara, Felicetto
Loscocco, Federica
Piccaluga, Pier Paolo
Fuligni, Fabio
Gazzola, Anna
Rossi, Maura
Laginestra, Antonella
Caraci, Maria Rita
Riccardi, Cira
Visani, Axel
Barulli, Sara
Guiducci, Barbara
Ricciardi, Teresa
Sparaventi, Giovanni
Rocchi, Marco
Isidori, Alessandro
BLOOD, 2013, 122 (21)
[8] Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients
Visani, G.
Ferrara, F.
Di Raimondo, F.
Loscocco, F.
Sparaventi, G.
Paolini, S.
Fuligni, F.
Gazzola, A.
Rossi, M.
Laginestra, M. A.
Caraci, M. R.
Riccardi, C.
Rocchi, M.
Visani, A.
Pileri, S. A.
Piccaluga, P. P.
Isidori, A.
LEUKEMIA, 2014, 28 (04) : 967 - 970
[9] Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients
G Visani
F Ferrara
F Di Raimondo
F Loscocco
G Sparaventi
S Paolini
F Fuligni
A Gazzola
M Rossi
M A Laginestra
M R Caraci
C Riccardi
M Rocchi
A Visani
S A Pileri
P P Piccaluga
A Isidori
Leukemia, 2014, 28 : 967 - 970
[10] Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial
Candoni, Anna
Papayannidis, Cristina
Martinelli, Giovanni
Simeone, Erica
Gottardi, Michele
Iacobucci, Ilaria
Gherlinzoni, Filippo
Visani, Giuseppe
Baccarani, Michele
Fanin, Renato
AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (05) : 655 - 663

← 1 2 3 4 5 →